Published
Anticoagulation prevents strokes in atrial fibrillation, but it does so by making a patient bleed more easily — and for some patients, that trade-off tips the wrong way. HAS-BLED is the score most widely used to estimate how much that bleeding risk actually is, and just as importantly, how much of it a clinician can do something about.
What HAS-BLED measures
HAS-BLED assigns one point each to nine criteria: uncontrolled hypertension, abnormal renal function, abnormal liver function, prior stroke, a history of bleeding or a bleeding predisposition, labile INR control (relevant only for patients on a vitamin K antagonist like warfarin), age over 65, use of bleeding-prone drugs such as NSAIDs or antiplatelet agents, and heavy alcohol use. The maximum is 9 points, though real-world scores of 4 or higher are unusual. It was derived by Pisters and colleagues from the same Euro Heart Survey cohort that produced CHA₂DS₂-VASc, published in 2010.
Why the score is about more than the number
It’s tempting to treat HAS-BLED like a stoplight: a low score means go, a high score means stop. That reading gets the tool’s purpose backwards. HAS-BLED was designed specifically to separate bleeding risk into what can and can’t be fixed, so a high score is meant to trigger a review of blood pressure control, concomitant NSAID or antiplatelet use, alcohol intake, and INR stability — not to justify withholding anticoagulation from a patient whose stroke risk, measured separately and typically with CHA₂DS₂-VASc, says they need it.
In fact, several HAS-BLED criteria — age, prior stroke, hypertension — also appear in stroke-risk scores, which is exactly why a patient can score high on both scales at once. That overlap isn’t a flaw in either tool; thrombotic and bleeding risk share real biological drivers, and the two scores are meant to be read side by side, not played off against each other.
A worked example
Take a 70-year-old patient with uncontrolled hypertension (systolic pressure persistently above 160 mmHg) who takes a daily over-the-counter NSAID for joint pain, with no renal or hepatic impairment, no prior stroke, no bleeding history, a stable INR, and no heavy alcohol use. That’s three points — one each for age, hypertension, and the NSAID — landing in the high-risk band. But look at what those three points actually are: two of them, blood pressure and NSAID use, are entirely modifiable. The correct response isn’t to reconsider anticoagulation; it’s to treat the hypertension and stop the NSAID, then reassess. Only “elderly” is fixed and unchangeable.
What counts as a “labile INR” on a DOAC?
Nothing — it scores as zero. That criterion specifically measures instability in INR control, which is only a meaningful concept for patients on a vitamin K antagonist such as warfarin. Patients on a direct oral anticoagulant aren’t monitored by INR at all, so the criterion simply doesn’t apply and contributes no points to their score.
Editverse’s free HAS-BLED calculator scores all nine criteria at once, breaks down exactly which ones are driving a patient’s total, and walks through this same worked example in more detail.
Clinical decision-support aid, not a substitute for clinical judgment. This tool implements a published scoring system for education and workflow support. It is not a medical device and has not been reviewed by the FDA or any regulatory body; results should always be interpreted by a qualified clinician alongside the full clinical picture.
References
- Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138(5):1093–1100.
Studying bleeding risk, anticoagulation safety, or drug-related adverse events using national survey data? Editverse’s NHANES Study service supports the full analysis pipeline for NHANES-based research — from cohort and variable selection through weighted statistical analysis and manuscript-ready output.